What is the appropriate dosing, route, duration, and monitoring for tranexamic acid in the management of non‑life‑threatening hematuria?

Tranexamic Acid for Non-Life-Threatening Hematuria

For non-life-threatening hematuria, tranexamic acid can be administered at 1 g intravenously every 6 hours as needed, or orally at 500 mg twice daily titrated up to 1000 mg four times daily, with mandatory dose reduction based on renal function. 1, 2

Dosing Regimens

Intravenous Administration

• Standard dose: 1 g IV, repeated every 6 hours if bleeding persists 1, 3
• Infusion rate: No more than 1 mL/minute (100 mg/minute) to avoid hypotension 4
• Duration: Typically 2-8 days depending on clinical response 4

Oral Administration

• Initial dose: Start at 500 mg twice daily 2
• Titration: Gradually increase up to 1000 mg four times daily or 1500 mg three times daily 2
• Duration: Continue until hematuria resolves, typically several days 2

Intravesical (Local) Administration for Bladder Hematuria

• Dose: 1000 mg injected through Foley catheter 5, 6
• Technique: Clamp catheter for 15 minutes after injection, then declamp and initiate continuous bladder irrigation if needed 5
• Evidence: Reduces duration of catheter placement (145 vs 308 minutes) and length of ED stay (274 vs 411 minutes) compared to irrigation alone 5

Mandatory Renal Dose Adjustments

Tranexamic acid is 90% renally cleared; failure to adjust dosing in renal impairment risks neurotoxicity and ocular toxicity. 7, 4

Serum Creatinine (mg/dL)	Recommended IV Dosing
1.36–2.83	10 mg/kg twice daily [4]
2.83–5.66	10 mg/kg once daily [4]
>5.66	10 mg/kg every 48 hours OR 5 mg/kg every 24 hours [4]

• These reductions apply to all routes and all doses throughout the treatment course 4, 8, 9
• In chronic kidney disease patients with polycystic kidney disease and severe hematuria, tranexamic acid has been used safely with appropriate dose adjustment 10, 11

Absolute Contraindications

Do NOT administer tranexamic acid in the following situations:

• Subarachnoid hemorrhage: Risk of cerebral edema and cerebral infarction 4
• Active intravascular clotting: Antifibrinolytic effect increases thrombotic risk 4
• Patients on warfarin for stroke prevention: Must reverse warfarin with prothrombin complex concentrate (PCC) or fresh frozen plasma PLUS vitamin K before considering tranexamic acid 12
• Severe hypersensitivity to tranexamic acid 4

Relative Contraindications & Cautions

• Recent thrombosis (within weeks to months): Avoid use 2
• Atrial fibrillation or known thrombophilia: Use with extreme caution; consider alternative hemostatic measures 2
• Concomitant prothrombotic medications: Avoid concurrent use with Factor IX concentrates, anti-inhibitor coagulant concentrates, or hormonal contraceptives 4
• Cirrhosis with invasive procedures: Routine use is discouraged due to lack of evidence and theoretical thrombotic risk 7

Monitoring Requirements

Clinical Monitoring

• Visual symptoms: Discontinue immediately if visual disturbances or ocular symptoms occur 4
• Neurological status: Monitor for seizures, particularly if inadvertent neuraxial administration is suspected 4
• Hemodynamic stability: Infuse slowly (≤1 mL/min) and monitor blood pressure 4
• Dizziness: Advise patients not to drive if dizziness occurs 4

Laboratory Monitoring

• Hemoglobin/hematocrit: Serial measurements to assess bleeding control 5, 6
• Renal function: Serum creatinine to guide dose adjustments 4, 8, 9
• Urinalysis: Microscopic hematuria assessment at 24 hours 6

Thromboembolic Surveillance

• No routine coagulation monitoring is required for tranexamic acid itself 1
• Maintain clinical vigilance for venous or arterial thromboembolism, though risk appears low when used appropriately 1, 10, 11

Duration of Therapy

• Typical course: 2-8 days for most hematuria cases 4
• Intravesical use: Single dose or repeated as needed; hematuria typically resolves within 24 hours 5, 6
• Chronic conditions (e.g., hereditary hemorrhagic telangiectasia): May require longer-term use with careful monitoring 2
• Discontinue once hematuria resolves or after 8 days if no response 4

Route Selection Algorithm

1. Mild hematuria (stable hemoglobin, no transfusion need): Oral tranexamic acid 500 mg twice daily, titrate as needed 2

2. Moderate hematuria (requiring IV iron or close monitoring): IV tranexamic acid 1 g every 6 hours OR intravesical 1000 mg if bladder source 1, 5

3. Severe hematuria (requiring transfusion, hemodynamic instability): IV tranexamic acid 1 g every 6 hours PLUS address underlying cause with endoscopic/surgical hemostasis 1

4. Bladder-specific hematuria (e.g., post-procedural, cystitis): Consider intravesical route first (1000 mg via catheter) before systemic administration 5, 6

Common Pitfalls to Avoid

• Failure to adjust for renal function: This is the most critical error; always calculate creatinine clearance before dosing 4, 8, 9
• Delayed administration in trauma: If hematuria is trauma-related, tranexamic acid must be given within 90 minutes of injury for mortality benefit; beyond 3 hours may cause harm 13, 14, 15
• Mixing with blood products: Never mix tranexamic acid injection with blood or penicillin-containing solutions 4
• Intrathecal administration: FOR INTRAVENOUS USE ONLY; inadvertent neuraxial injection causes seizures and cardiac arrhythmias 4
• Use in cirrhosis without indication: Routine prophylactic use before procedures in cirrhosis is not recommended 7
• Ignoring visual symptoms: Any visual changes mandate immediate discontinuation 4

Special Populations

Elderly with Prior Stroke

• Absolute contraindication if on warfarin without reversal 12
• Renal dose adjustment is mandatory (elderly often have reduced creatinine clearance) 4, 8
• Monitor closely for thrombotic events given baseline stroke risk 12

Polycystic Kidney Disease

• Tranexamic acid is effective and safe for severe hematuria from cyst rupture 10, 11
• Dose adjustment for renal impairment is essential 10, 11
• Typically resolves bleeding within 2-5 days 11
• May prevent need for embolization or nephrectomy 11

Anticoagulated Patients

• On NOACs (dabigatran, rivaroxaban, apixaban, edoxaban): Tranexamic acid can be considered as adjuvant therapy for non-life-threatening bleeding at 1 g IV every 6 hours 1
• On warfarin: Reverse with PCC (50 U/kg) or FFP PLUS vitamin K (10 mg IV) before considering tranexamic acid 12
• Maintain adequate diuresis to facilitate NOAC clearance 1